Induction of osteogenesis by bone-targeted Notch activation

Area of Science:

• Bone Biology and Regenerative Medicine
• Cell Signaling and Therapeutics

Background:

• Declining bone mass, associated with aging and osteoporosis, increases fracture risk.
• Bone homeostasis depends on cellular interactions involving vascular cells and mesenchymal stromal cells (MSCs).
• Notch signaling pathways regulate these crucial cellular interactions in bone development and maintenance.

Purpose of the Study:

• To investigate the therapeutic potential of secreted Notch ligand proteins for enhancing osteogenesis.
• To evaluate the efficacy and specificity of a bone-targeting Delta-like 4 (Dll4) fusion protein in adult mice.

Main Methods:

• Administration of a high-affinity, bone-targeting Notch ligand fusion protein (Dll4(E12)) to adult male, female, and ovariectomized mice.
• Assessment of osteogenesis and bone formation markers.
• Single-cell RNA sequencing analysis of stromal cells to identify targeted cell populations.

Main Results:

• Dll4(E12) treatment significantly induced bone formation in male mice without adverse effects in other organs.
• The therapy was less effective in female and ovariectomized mice but showed enhanced trabecular bone formation when combined with parathyroid hormone.
• Single-cell analysis revealed that Dll4(E12) primarily targets MSCs, with minimal impact on osteoblasts, endothelial cells, or chondrocytes.

Conclusions:

• Bone-targeted Notch signaling activation via fusion proteins like Dll4(E12) is a promising strategy for promoting osteogenesis.
• This approach offers potential therapeutic benefits for osteoporosis and age-related bone loss.
• The targeted delivery mechanism may mitigate systemic side effects associated with Notch pathway modulation.